[{"orgOrder":0,"company":"SteinCares","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase I","graph3":"SteinCares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SteinCares \/ SteinCares","highestDevelopmentStatusID":"6","companyTruncated":"SteinCares \/ SteinCares"},{"orgOrder":0,"company":"SteinCares","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Sugemalimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"SteinCares","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SteinCares \/ SteinCares","highestDevelopmentStatusID":"15","companyTruncated":"SteinCares \/ SteinCares"},{"orgOrder":0,"company":"SteinCares","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"COSTA RICA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"SteinCares","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SteinCares \/ Lupin Ltd","highestDevelopmentStatusID":"10","companyTruncated":"SteinCares \/ Lupin Ltd"}]

Find Clinical Drug Pipeline Developments & Deals by SteinCares

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Bio-Thera will be responsible for development and supply of a proposed biosimilar of dupilumab, while SteinCares will lead the registration and commercialization across Latin America.

                          Product Name : BAT2406

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          June 25, 2025

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Recipient : Bio-Thera Solutions

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : SteinCares will handle all regulatory filings, registrations and commercialisation of LUBT010 (ranibizumab) in Latin America, while Lupin will be responsible for manufacturing the same.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          May 26, 2025

                          Lead Product(s) : Ranibizumab

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Lupin Ltd

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Under this agreement, SteinCares will gain the commercialization rights for Cejemly (sugemalimab) in 10 LATAM countries.

                          Product Name : Cejemly

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          January 26, 2025

                          Lead Product(s) : Sugemalimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : CStone Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank